secwatch / observer

8-K filed June 2, 2026, 4:00 PM ET ticker INMB CIK 0001711754

other material confidence high sentiment positive materiality 0.75

INmune Bio reports statistically significant white matter MRI biomarker in Phase 2 Alzheimer's trial

Inmune Bio, Inc.

XPro1595 showed significant myelin improvement vs placebo in full mITT (p=0.0028, d=0.46, n=200).
Biomarker-enriched patients (inflammation) showed stronger effect (p=0.0098, d=0.59, n=100).
FDA granted Fast Track designation on May 14, 2026; End-of-Phase 2 alignment secured for Phase 2b/3.
No ARIA-E or ARIA-H observed; favorable safety profile differentiates from amyloid-targeting therapies.
Complete dataset to be presented at AAIC 2026 (July 12-15, London).

item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001213900-26-064144
form_type: 8-K
ticker: INMB
cik: 0001711754
company_name: Inmune Bio, Inc.
filed_at: 2026-06-02T20:00:20+00:00
discovered_at: 2026-06-02T20:01:00.682870+00:00
generated_at: 2026-06-02T20:01:12.246613+00:00
sec_items: ["8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001213900-26-064144
json_url: https://secwatch.observer/filing/0001213900-26-064144.json
markdown_url: https://secwatch.observer/filing/0001213900-26-064144.md
text_url: https://secwatch.observer/filing/0001213900-26-064144.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/0001213900-26-064144-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1711754/000121390026064144/ea0293325-8k_inmune.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

XMTR

Xometry announces public offering of 2.65M shares at $85.00; expected net proceeds $215.2M

Xometry, Inc. June 2, 2026, 5:26 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

HYMC

Hycroft TRS shows $10B NPV at spot; 51-year mine life with 10.4M oz gold

HYCROFT MINING HOLDING CORP June 2, 2026, 4:31 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

TTI

TETRA announces $100M common stock offering, Arkansas Bromine Project approved with $220M remaining capex

TETRA TECHNOLOGIES INC June 2, 2026, 4:26 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CEG

Constellation Energy secondary offering of 11M shares with concurrent $558M share repurchase

Constellation Energy Corp June 2, 2026, 4:15 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CNL Strategic Capital, LLC

Shareholders reject enhanced liquidity plan (25% repurchase); loan amended for equity buybacks

CNL Strategic Capital, LLC June 2, 2026, 4:04 PM ET other_material Items 1.01, 2.03, 5.07, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

QMCO

Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance

QUANTUM CORP /DE/ June 2, 2026, 10:41 AM ET other_material Items 1.01, 2.02, 2.03, 3.02, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CELC

Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial

Celcuity Inc. June 2, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

FLGT

Fulgent Genetics reports encouraging Phase 2 data for FID-007 in HNSCC at ASCO 2026

Fulgent Genetics, Inc. June 1, 2026, 7:07 PM ET other_material Items 8.01, 9.01

same SEC item: 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001213900-26-064144

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.